510(k) device
CP Relief Wand Rx - TENS/NMES
N & C Holdings, LLC · Stimulator, Nerve, Transcutaneous, For Pain Relief (GZJ, Class II) · First FDA decision Aug 15, 2025, newest Aug 15, 2025Chronic pain
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
136
Naming "CP"
MAUDE reports
23,477
Brand "CP", since 2015
PubMed studies
97,173
Mentioning "CP"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing CP Relief Wand Rx - TENS/NMES
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K252236 · Decided Aug 15, 2025 · 29 days after receipt
Device type: Stimulator, Nerve, Transcutaneous, For Pain Relief (GZJ) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Continuous Peripheral Nerve Blocks (CPNB)Local determinationIn effectL37641Palmetto GBAUpdated Jun 16, 2022
- Extracorporeal Photopheresis (ECP)National analysisReview closedCAG-00324R2Updated Sep 17, 2026
- External Counterpulsation (ECP) TherapyNational analysisReview closedCAG-00002R2Updated Sep 17, 2026
- Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA)National analysisReview closedCAG-00093R2Updated Sep 17, 2026
- Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA)National analysisReview closedCAG-00093RUpdated Sep 17, 2026
- Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA)National analysisReview closedCAG-00093NUpdated Sep 15, 2026
- Glycated Hemoglobin/Glycated Protein (Addition of CPT Code 83037, Hemoglobin; glycosylated [A1c] by device cleared by FDA for home use)Coding analysisReview closedCAG-00373NUpdated Sep 14, 2026
- External Counterpulsation (ECP) TherapyNational analysisReview closedCAG-00002RUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "CP", any status and sponsor, newest update first.
- Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)Pivotal-lookingRecruiting
Supira MedicalNot on our public-company list
NCT07296744 · 358 participants (planned) · Start May 11, 2026 · Primary completion Nov 2027
Device: The Supira System; Impella · For: Coronary Artery Disease; High Risk Percutaneous Coronary Intervention; Interventional Cardiology and 1 more
Sites: Loma Linda, California; Sacramento, California; Thousand Oaks, California · 27 sites in all
135 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "CP", and for the whole product code for context.
This brand
23,477 reports: 7,312 malfunction, 13,417 injury, 2,742 death
Whole product code GZJ
239 reports: 42 malfunction, 195 injury, 0 death
Newest reports for this brand
- Impella CPMalfunction
1220648-2026-14129 · Received Oct 30, 2026 · Event dated Oct 7, 2026
Device type: Temporary Non-Roller Type Left Heart Support Blood Pump (OZD)
Device problem as coded: Component Missing
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "CP"[tiab]. The summary above synthesizes these.
- Clinical characteristics of smoking-related chronic pancreatitis.
Hao L, Liu Y, Dong ZQ, et al. · Front Cell Infect Microbiol · 2022Research Support, Non-U.S. Gov't
- Cerebral palsy registries.
Cans C, Surman G, McManus V, et al. · Semin Pediatr Neurol · 2004Research Support, Non-U.S. Gov't, Review
- The Capsular Polysaccharide Obstructs Wall Teichoic Acid Functions in Staphylococcus aureus.
Lehmann E, van Dalen R, Gritsch L, et al. · J Infect Dis · 2024Research Support, Non-U.S. Gov't
- Causative factors in cerebral palsy.
Nelson KB · Clin Obstet Gynecol · 2008Research Support, N.I.H., Intramural, Review
- Compartmentalized pressurization is a novel prognostic factor for hypercontractile esophagus.
Leopold AR, McCarthy P, Nair A, et al. · Neurogastroenterol Motil · 2024Research Support, N.I.H., Extramural
- Mechanism of actin capping protein recruitment and turnover during clathrin-mediated endocytosis.
Lamb AK, Fernandez AN, Eadaim A, et al. · J Cell Biol · 2024Research Support, U.S. Gov't, Non-P.H.S.
- Which is the Most Common Physiologic Type of Cerebral Palsy?
Kamate M, Detroja M · Neurol India · 2022
- Dysarthria syndromes in children with cerebral palsy.
Schölderle T, Haas E, Ziegler W · Dev Med Child Neurol · 2021Research Support, Non-U.S. Gov't
- Insights From Genetic Studies of Cerebral Palsy.
Lewis SA, Shetty S, Wilson BA, et al. · Front Neurol · 2020Review
- Genetic Risk Factors in Early-Onset Nonalcoholic Chronic Pancreatitis: An Update.
Wertheim-Tysarowska K, Oracz G, Rygiel AM · Genes (Basel) · 2021Research Support, Non-U.S. Gov't, Review
- Epidemiological Characteristics of Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae Colonization.
Jeong IS, Song JY · Asian Nurs Res (Korean Soc Nurs Sci) · 2022
- Electroacupuncture activates the peroxisome proliferators-activated receptor pathway to improve the phenotype of cerebral palsy.
Wu ZF, Peng HH, Shu Y, et al. · CNS Neurosci Ther · 2024Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code GZJ.
- Electro-Nerve Stimulator Tens, Model BMLS06-1Biomedical Life Systems, Inc. · 510(k) 2006
- Transcutaneous Electrical Nerve Stimulator (model: TENS WMPS6-1)Wuxi Jiajian Medical Instrument Co., Ltd. · 510(k) 2023
- ReliefBandReliefband Technologies, LLC · 510(k) 2019
- SensusNeurometrix, Inc. · 510(k) 2013
- Quadra Bloc TENS PlusGradient Technologies, LLC · 510(k) 2011
- Combocare 2000Xanacare Technologies, LLC · 510(k) 2008
- STIMPOD NMS460 Nerve StimulatorAlgiamed Technologies USA, Inc. · 510(k) 2026
- actiTENS miniSublimed · 510(k) 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.